Schroder Investment Management Group Trims Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Schroder Investment Management Group cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 94.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,536 shares of the company’s stock after selling 63,731 shares during the quarter. Schroder Investment Management Group’s holdings in Medpace were worth $1,179,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. R Squared Ltd purchased a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace in the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC increased its holdings in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its position in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MEDP shares. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus target price of $376.30.

Medpace Stock Down 5.6 %

Shares of NASDAQ:MEDP opened at $287.11 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $282.42 and a fifty-two week high of $459.77. The firm’s 50 day moving average price is $331.56 and its 200 day moving average price is $337.32. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.